Volume 6, Issue 4 (1-2016)                   JAP 2016, 6(4): 66-76 | Back to browse issues page

XML Persian Abstract Print


1- Iran University of Medical Sciences
2- Iran University of Medical Sciences , ravaghih@gmail.com
3- University of Social Welfare and Rehabilitation Sciences
Abstract:   (6987 Views)

Abstract:

Aims and Background: Nausea and vomiting after surgery is one of the undesirable complications which occurs in more than %30 of patients. In the meanwhile, Serotonin antagonists have an expanded function in prevention of postoperative nausea and vomiting. The aim of this research was to compare the effectiveness of Ondansetron and Palonosetron(Serotonin antagonist) in this regard.

Materials and Methods: This research has been an organized review with Meta-analysis. Search process has been done in Data bases namely: Clinicaltrials.Gov, CRD Database, Cochrane Systematic Review, Clinical key, and Pub Med just RCT articles ,which compared incidence of postoperative nausea and vomiting under general anesthesia ,have been chosen. After search and evaluation, 8 articles entered Meta-analysis. Risk estimation integration, and risk ratio calculation were analyzed via STATA 13.

Findings: Number of samples in articles were 739. The incidence of Postoperative nausea and vomiting was assessed until 24 hours after surgery in 389 persons. Data analysis during 0 to 24 hours showed that Palonosetron decreased the  incidence of nausea by %50 , and the incidence of vomiting by  79% in comparison with Ondansetron (p= 0.001)

Conclusions: Evaluating the effect of 0.075 mg Palonosetron versus 4mg of Ondansetron in primary 24 hours past surgery demonstrated that Palonestron has more efficiency on incidence reduction of Nausea and Vomiting, compared to Ondansetron in patients.

Full-Text [PDF 390 kb]   (2071 Downloads)    
Type of Study: Review | Subject: Anesthesia pharmacology
Received: 2015.04.29 | Accepted: 2015.08.14 | Published: 2015.12.27

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.